Vera Therapeutics says ORIGIN 3 final TRUTAKNA efficacy data for IgA nephropathy at ASN Kidney Week 2026
VERA•Vera Therapeutics said final efficacy results from the Phase 3 ORIGIN 3 trial of TRUTAKNA in IgA nephropathy will be presented in a late-breaking talk on Oct. 22 at ASN Kidney Week 2026.
1. Presentation schedule
Final efficacy results from the Phase 3 ORIGIN 3 trial of TRUTAKNA in IgA nephropathy are scheduled for a late-breaking opening plenary talk on Oct. 22. Separate interim data from the Phase 2 PIONEER basket study in adult IgA nephropathy and primary membranous nephropathy are slated for Oct. 24.
